About the International Journal of Prostate Cancer
A specialized peer-reviewed journal dedicated to advancing molecular and pathophysiological understanding of prostate cancer through rigorous scientific investigation and open access dissemination.
IJPC publishes research that illuminates the fundamental biological processes driving prostate cancer pathogenesis. Our scope encompasses molecular genetics, cellular signaling networks, disease progression mechanisms, and biomarker discovery—all focused on understanding how the disease works rather than how it is clinically managed.
Genetic & Epigenetic Alterations
Somatic mutations, chromosomal rearrangements, DNA methylation patterns, histone modifications, and chromatin remodeling in prostate carcinogenesis.
Signaling Pathway Dysregulation
Androgen receptor signaling, PI3K/AKT/mTOR pathway, MAPK cascades, Wnt/β-catenin, and aberrant growth factor signaling in tumor progression.
Tumor Microenvironment Interactions
Stromal-epithelial cross-talk, immune cell infiltration, angiogenic factors, extracellular matrix remodeling, and paracrine signaling mechanisms.
Molecular Biomarker Discovery
Identification and validation of genomic, proteomic, metabolomic, and circulating biomarkers reflecting disease mechanisms and progression states.
Cell Cycle & Apoptosis Regulation
Checkpoint dysregulation, p53 pathway alterations, apoptotic resistance mechanisms, and cellular senescence in prostate cancer cells.
Metastatic Cascade Mechanisms
Epithelial-mesenchymal transition, invasion molecular machinery, circulating tumor cell biology, and organotropic metastasis pathways.
Cancer Stem Cell Biology
Stem-like cell populations, self-renewal mechanisms, lineage plasticity, and progenitor cell contributions to tumor heterogeneity.
Disease Model Systems
Development and characterization of cell lines, organoids, patient-derived xenografts, genetically engineered mouse models for mechanistic studies.
Key Molecular Pathways Investigated
- Androgen receptor splice variants
- PTEN loss mechanisms
- TMPRSS2-ERG fusion biology
- DNA damage response pathways
- Metabolic reprogramming
- Autophagy regulation
- MicroRNA networks
- Long non-coding RNA functions
- Protein degradation machinery
- Reactive oxygen species signaling
- Hypoxia response mechanisms
- Cell adhesion molecule alterations
IJPC values diverse experimental methodologies that rigorously interrogate disease mechanisms:
- Molecular Biology: Gene expression profiling, CRISPR/Cas9 editing, RNA interference studies, reporter assays, chromatin immunoprecipitation
- Cell Biology: Live-cell imaging, organoid culture systems, 3D invasion assays, cell cycle analysis, migration/proliferation studies
- Biochemistry: Protein-protein interactions, enzyme kinetics, post-translational modifications, metabolic flux analysis
- Omics Technologies: Genomics, transcriptomics, proteomics, phosphoproteomics, metabolomics, lipidomics
- Animal Models: Conditional knockout mice, transgenic models, orthotopic implantation, metastasis tracking systems
- Computational Biology: Pathway modeling, network analysis, bioinformatics pipelines, systems biology integration
Peer Review Excellence
IJPC employs a single-blind peer review process conducted by expert reviewers with deep knowledge in prostate cancer pathophysiology. Reviewers assess experimental design rigor, methodological appropriateness, statistical validity, mechanistic interpretation, and reproducibility considerations.
Manuscripts are evaluated based on:
- Scientific novelty and mechanistic insight
- Experimental rigor and technical quality
- Appropriate controls and replication
- Statistical analysis robustness
- Clear presentation of findings
- Mechanistic interpretation accuracy
Publication Timeline
IJPC is committed to rapid dissemination without compromising quality:
- Initial screening: 3-5 business days
- Peer review completion: 10-20 days
- Revision assessment: 5-10 days
- Acceptance to online publication: 2-5 days
- DOI assignment and indexing: Immediate
Authors receive detailed feedback regardless of decision outcome, supporting continuous improvement of scientific communication.
Editorial Leadership
IJPC's editorial board comprises internationally recognized experts in prostate cancer biology, molecular oncology, and experimental pathology. Our editors bring diverse expertise spanning genomics, cell signaling, tumor biology, and translational research—ensuring comprehensive evaluation of submitted manuscripts from multiple perspectives.
Editorial decisions prioritize mechanistic rigor, experimental reproducibility, and contributions to fundamental understanding of prostate cancer pathophysiology.
IJPC welcomes original research articles, comprehensive reviews, short communications, and methodological papers focused on prostate cancer pathophysiology and molecular mechanisms.
- Structure: Abstract, Introduction, Materials and Methods, Results, Discussion, Conclusions, References
- Length: Research articles up to 6,000 words; reviews up to 8,000 words (excluding references)
- Figures/Tables: High-resolution images with detailed legends; supplementary data encouraged
- Methods: Sufficient detail for reproducibility; reagent sources, antibody validation, statistical tests specified
- Data Availability: Raw data deposition in public repositories encouraged; accession numbers required
Complete formatting guidelines are available in our Instructions for Authors.
Manuscripts can be submitted through multiple channels:
- Online Submission System (preferred)
- Email submission to [email protected]
- Manuscript Zone platform
IJPC operates under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, ensuring maximum visibility and impact for published research.
- Global Accessibility: Immediate free access for researchers worldwide without subscription barriers
- Broad Indexing: Inclusion in major scientific databases and search engines
- Citation Advantage: Open access articles demonstrate higher citation rates and broader research impact
- Copyright Retention: Authors retain copyright while granting publication rights
- Reuse Rights: Findings can be incorporated into presentations, teaching materials, and derivative works
- Rapid Dissemination: Accelerated publication timeline compared to traditional subscription journals
Specialized Focus
Dedicated exclusively to prostate cancer mechanisms, ensuring your work reaches the most relevant scientific audience.
Expert Review
Evaluation by specialists in prostate cancer pathophysiology who understand nuanced mechanistic research.
Rapid Publication
Efficient editorial workflows prioritize timely dissemination of significant mechanistic findings.
Global Reach
Open access model ensures your discoveries reach international research community without geographic restrictions.
Advance Prostate Cancer Mechanistic Understanding
Join the global community of researchers investigating the molecular foundations of prostate cancer. Submit your mechanistic discoveries, biomarker validation studies, and pathophysiological investigations to IJPC.
